Dendritic Cell Vaccination

Phase 2Biologic

UUniversity of Michigan Rogel Cancer Center

Dendritic Cell Vaccination is one of 168 biologic programs targeting Pancreatic Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

167

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic CarcinomaActive, not recruiting

Malignant Pleural MesotheliomaActive, not recruiting

Breast CancerActive, not recruiting

MelanomaActive, not recruiting

Myeloid LeukemiaActive, not recruiting

Pancreatic CarcinomaPhase 1

Active, not recruiting

Malignant Pleural MesotheliomaPhase 1/Phase 2

Active, not recruiting

Breast CancerPhase 1

Active, not recruiting

MelanomaPhase 1/Phase 2

Active, not recruiting

Myeloid LeukemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Trodelvy

Gilead

Preclinical

37 2

Dendritic Cell Vaccination

UUniversity of Michigan Rogel Cancer Center

Phase 2

2 3

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

1 4

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

1 5

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 6

Tetracycline Hydrochloride

EEuropean Organisation for Research and Treatment of Cancer - EORTC

Preclinical

1 7

Leronlimab

CCytoDyn, Inc.

Preclinical

1 8

QBX258

Novartis

Preclinical

1 9

Aromasin

Pfizer

Preclinical

6 10

Sandostatin

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Malignant Pleural Mesothelioma

NCT05765084

Clinical

Trials by Indication[1]

Breast Cancer2 trials

A Phase I Cancer Vaccine Study for Patients With Metastatic Breast Cancer

Unknown status·SSouthern Cancer Center·Phase 1·NCT00715832·25 enrolled

Cellular Immunotherapy Study With Autologous Dendritic Cells Loaded With Oncofetal Antigen/iLRP in Patients With Metastatic Breast Cancer

Unknown status·QQuantum Immunologics, Inc.·Phase 1/2·NCT00879489·24 enrolled

Melanoma1 trial

Vaccination of Patients With Stage IV Melanoma With Dendritic Cells

Completed·—·Phase 1/2·NCT00125749·30 enrolled

Pancreatic Carcinoma1 trial

A Pilot Study Assessing Intra-Metastasis Administration of Autologous KLH-pulsed Dendritic Cells With Tumoral Radiation Therapy in Patients With Metastatic Pancreatic Carcinoma

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT00843830·4 enrolled

Malignant Pleural Mesothelioma1 trial

Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma

Recruiting·UUniversity Hospital, Antwerp·Phase 1/2·NCT05765084·15 enrolled

Myeloid Leukemia1 trial

Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma

Completed·ZZwi Berneman·Phase 2·NCT00965224·38 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Dendritic Cell Vaccination. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dendritic Cell Vaccination compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dendritic Cell Vaccination. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Michigan Rogel Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Michigan Rogel Cancer Center

Dendritic Cell Vaccination

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Breast Cancer2 trials

Melanoma1 trial

Pancreatic Carcinoma1 trial

Malignant Pleural Mesothelioma1 trial

Myeloid Leukemia1 trial

References

Drug Info

Quick Facts

Related News